Also trades as: HOFBF (OTC) · $vol 0M
HBC.OL OSL
Hofseth BioCare ASA
1W: -5.7%
1M: -3.6%
3M: -11.3%
YTD: -1.5%
1Y: -30.0%
3Y: -56.2%
5Y: -82.0%
kr 1.33 ($0.14)
+0.03 (+2.31%)
Weekly Expected Move ±9.1%
kr 1
kr 1
kr 1
kr 1
kr 2
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$254M
-1.2% ▼
5Y CAGR: +29.7%
Gross Profit
-$32M
-137.0% ▼
Operating Income
-$113M
+1.1% ▲
Net Income
-$135M
-9.3% ▼
EPS (Diluted)
$-0.33
-10.0% ▼
EBITDA
-$73M
-7.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $88M | $120M | $195M | $257M | $254M |
| YoY Growth | +26.5% | +37.5% | +61.8% | +32.1% | -1.2% |
| Cost of Revenue | $65M | $92M | $151M | $170M | $287M |
| Gross Profit | $23M | $29M | $44M | $88M | -$32M |
| Gross Margin | 26.4% | 23.7% | 22.7% | 34.1% | -12.8% |
| R&D Expenses | $13M | $14M | $11M | $15M | $0 |
| SG&A Expenses | $45M | $33M | $35M | $81M | $87M |
| Operating Expenses | $142M | $157M | $147M | $96M | $80M |
| Operating Income | -$119M | -$129M | -$103M | -$114M | -$113M |
| Operating Margin | -135.3% | -106.8% | -52.6% | -44.3% | -44.3% |
| Interest Expense | $9M | $10M | $8M | $16M | $23M |
| Income Before Tax | -$126M | -$137M | -$107M | -$125M | -$135M |
| Tax Expense | $0 | $1M | $0 | $0 | $176K |
| Net Income | -$126M | -$137M | -$107M | -$123M | -$135M |
| Net Margin | -144.3% | -114.1% | -54.7% | -47.9% | -53.0% |
| EPS (Diluted) | $-0.35 | $-0.37 | $-0.27 | $-0.30 | $-0.33 |
| EBITDA | -$88M | -$97M | -$63M | -$68M | -$73M |
| Shares Outstanding | 358M | 375M | 395M | 412M | 411M |